A myeloablative conditioning regimen with fludarabine demonstrates good results in UCBT for 30 pediatric patients with hematologic malignancies, Especially acute lymphoblastic leukemia

Neoplasma

Volumn 61, Issue 5, 2014, Pages 593-600

  Tong, J ^a   Sun, Z ^a   Liu, H ^a   Geng, L ^a   Ding, K ^a   Wang, X ^a   Zheng, C ^a   Tang, B ^a   Zhu, X ^a   Yao, W ^a   Song, K ^a   Liu, X ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Conditioning regimen; Cord blood transplant; Fludarabine; Hematologic malignancies

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; VIDARABINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOODSTREAM INFECTION; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; DIARRHEA; DISEASE COURSE; ELECTROCORTICOGRAPHY; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HEMORRHAGIC CYSTITIS; HUMAN; MALE; MORTALITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT CARE; PEDIATRICS; PRESCHOOL CHILD; RASH; SCHOOL CHILD; SINGLE DRUG DOSE; UMBILICAL CORD BLOOD; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; GRAFT VS HOST DISEASE; IMMUNOSUPPRESSIVE TREATMENT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE;

ADOLESCENT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MYELOABLATIVE AGONISTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 84907283632     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_073     Document Type: Article

References (36)

1. Benito AI, Diaz MA, Gonzalez-Vicent M, Sevilla J, Madero L. Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplant 2004; 33: 675–690. http://dx.doi.org/10.1038/sj.bmt.1704405
2. Cohen Y, Nagler A. Umbilical cord blood transplantation– how, when, and for whom? Blood Rev 2004; 18: 167–179. http://dx.doi.org/10.1016/S0268-960X(03)00064-X
3. Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008; 127: 286–297. http://dx.doi.org/10.1016/j.clim.2008.02.008
4. Gutman JA, Leisenring W, Appelbaum FR, Woolfrey AE, Delaney C. Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biol Blood Marrow Transplant 2009; 15: 1122–1129. http://dx.doi.org/10.1016/j.bbmt.2009.05.014
5. Baek HJ, Kook H, Han DK, Hwang TJ. Hematopoietic stem cell transplantation in children with leukemia: a single institution experience with respect to donors. J Korean Med Sci 2011; 26: 1548–1555. http://dx.doi.org/10.3346/jkms.2011.26.12.1548
6. Bertaina A, Bernardo ME, Caniglia M, Vinti L, Giorgiani G et al. Cord blood transplantation in children with haematological malignancies. Best Pract Res Clin Haematol 2010; 23: 189–196. http://dx.doi.org/10.1016/j.beha.2010.06.005
7. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285. http://dx.doi.org/10.1056/NEJMoa041469
8. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813–3820. http://dx.doi.org/10.1182/blood-2004-03-1001
9. Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007; 109: 1322–1330. http://dx.doi.org/10.1182/blood-2006-04-020172
10. Oran B, Shpall E. Umbilical cord blood transplantation: a maturing technology. Hematology Am Soc Hematol Educ Program 2012; 2012: 215–222.
11. Sato A, Ooi J, Takahashi S, Tsukada N, Kato S et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant 2011; 46: 257–261. http://dx.doi.org/10.1038/bmt.2010.91
12. Sun ZM, Liu HL, Geng LQ, Zhou CY, WANG XB et al. Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies. Zhonghua Yi Xue Za Zhi 2012; 92: 1660–1664.
13. Koo HH, Ahn HS. Umbilical cord blood transplantation. Korean J Pediatr 2012; 55: 219–223. http://dx.doi.org/10.3345/kjp.2012.55.7.219
14. Sauter C, Abboud M, Jia X, Heller G, Gonzales AM et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011; 17: 1460–1471. http://dx.doi.org/10.1016/j.bbmt.2011.02.001
15. Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N et al. Early immune reaction after reducedintensity cord-blood transplantation for adult patients. Transplantation 2005; 80: 34–40. http://dx.doi.org/10.1097/01.TP.0000163289.20406.86
16. Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB et al. Fludarabine- based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007; 13: 1313–1323. http://dx.doi.org/10.1016/j.bbmt.2007.07.006
17. Bolanos-Meade J, Luznik L, Muth M, Matsui WH, Huff CA et al. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant 2009; 43: 477–480. http://dx.doi.org/10.1038/bmt.2008.353
18. Huang XJ, Wang Y, Liu DH, Xu LP, Chen H et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study. J Clin Immunol 2008; 28: 390–397. http://dx.doi.org/10.1007/s10875-008-9193-4
19. Liu HL, Sun ZM, Geng LQ, Wang XB, Ding KY et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reducedintensity conditioning: high graft rejection, but good survival. Bone Marrow Transplant 2012; 47: 1186–1190. http://dx.doi.org/10.1038/bmt.2011.251
20. Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft versus-malignancy. Curr Opin Oncol 1999; 11: 87–95. http://dx.doi.org/10.1097/00001622-199903000-00003
21. Catapano CV, Chandler KB, Fernandes DJ. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res 1991; 51: 1829–1835.
22. Andersson BS, Valdez BC, DE Lima M, Wang X, Thall PF et al. Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 2011; 17: 893–900. http://dx.doi.org/10.1016/j.bbmt.2010.09.022
23. GANDHI V, PLUNKETT W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93–103. http://dx.doi.org/10.2165/00003088-200241020-00002
24. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, BASSETT R et al. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma 2012; 53: 901–906. http://dx.doi.org/10.3109/10428194.2011.631159
25. Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K et al. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant 2012; 18: 963–968. http://dx.doi.org/10.1016/j.bbmt.2012.02.012
26. Daly A, Savoie ML, Geddes M, Chaudhry A, Stewart D et al. Fludarabine, Busulfan, Antithymocyte Globulin, and Total Body Irradiation for Pretransplantation Conditioning in Acute Lymphoblastic Leukemia: Excellent Outcomes in All but Older Patients with Comorbidities. Biol Blood Marrow Transplant 2012; 18: 1921–1926. http://dx.doi.org/10.1016/j.bbmt.2012.07.017
27. Brunstein CG. Umbilical cord blood transplantation for the treatment of hematologic malignancies. Cancer Control 2011; 18: 222–236.
28. Michel G, Rocha V, Chevret S, Arcese W, Chan KW et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003; 102: 4290–4297. http://dx.doi.org/10.1182/blood-2003-04-1288
29. Wall DA, Carter SL, Kernan NA, Kapoor N, Kamani NR et al. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. Biol Blood Marrow Transplant 2005; 11: 637–646. http://dx.doi.org/10.1016/j.bbmt.2005.05.003
30. Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008; 112: 4318–4327. http://dx.doi.org/10.1182/blood-2007-06-098020
31. Frangoul H, Wang L, Harrell FE JR, Ho R, Domm J. Preengraftment syndrome after unrelated cord blood transplant is a strong predictor of acute and chronic graftversus- host disease. Biol Blood Marrow Transplant 2009; 15: 1485–488. http://dx.doi.org/10.1016/j.bbmt.2009.07.001
32. Patel KJ, Rice RD, Hawke R, Abboud M, Heller G et al. Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versushost disease. Biol Blood Marrow Transplant 2010; 16: 435–440. http://dx.doi.org/10.1016/j.bbmt.2009.10.022
33. Wang X, Liu H, Li L, Geng L, Ding K et al. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies. Eur J Haematol 2012; 88: 39–45. http://dx.doi.org/10.1111/j.1600-0609.2011.01709.x
34. Saavedra S, Sanz GF, Jarque I, Moscardo F, Jimenez C et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant 2002; 30: 937–943. http://dx.doi.org/10.1038/sj.bmt.1703764
35. Beck JC, Wagner JE, Defor TE, Brunstein CG, Schleiss MR et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 215–222. http://dx.doi.org/10.1016/j.bbmt.2009.09.019
36. Milano F, Pergam SA, Xie H, Leisenring WM, Gutman JA et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011 118: 5689–5696. http://dx.doi.org/10.1182/blood-2011-06-361618